Zoetis Inc. (LON:0M3Q)
London · Delayed Price · Currency is GBP · Price in USD 128.26
+0.78 (0.61%)
At close: Nov 28, 2025
Zoetis Employees
Zoetis had 13,800 employees as of December 31, 2024. The number of employees decreased by 300 or -2.13% compared to the previous year.
Employees
13,800
Change (1Y)
-300
Growth (1Y)
-2.13%
Revenue / Employee
506.58K GBP
Profits / Employee
142.91K GBP
Market Cap
42.67B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13,800 | -300 | -2.13% |
| Dec 31, 2023 | 14,100 | 300 | 2.17% |
| Dec 31, 2022 | 13,800 | 1,700 | 14.05% |
| Dec 31, 2021 | 12,100 | 800 | 7.08% |
| Dec 31, 2020 | 11,300 | 700 | 6.60% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Spire Healthcare Group | 15,703 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
Zoetis News
- 3 days ago - Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs - Business Wire
- 8 days ago - Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst - Benzinga
- 9 days ago - Zoetis (ZTS) Coverage Initiated with Sector Weight Rating by KeyBanc - GuruFocus
- 9 days ago - A Look Into Zoetis Inc's Price Over Earnings - Benzinga
- 9 days ago - Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 10 days ago - Zoetis to Host Innovation Webcast - Business Wire
- 11 days ago - Zoetis (ZTS): Analyst Stifel Maintains Hold, Lowers Price Target to $130 | ZTS Stock News - GuruFocus
- 12 days ago - These stocks have been hit hard in 2025 but could surge by as much as 57% from here - Market Watch